Introduction:
IX.B. Structures and processes
IX.B.1. Sources of data and information
IX.B.3. Evaluation during signal validation and further assessment
IX.C. Operation of the EU network
IX.C.1. Roles and responsibilities
IX.C.1.1. Responsibilities of the marketing authorisation holder in the
EU
IX.C.1.2. Responsibilities within the EU regulatory network
IX.C.2. Emerging safety issues
IX.C.3. Monitoring of EudraVigilance data
IX.C.3.1. Principles for access
IX.C.3.2. Periodicity of monitoring
IX.C.3.3. Analysis of EudraVigilance data
IX.C.4.1. Variation of the terms of marketing authorisation
IX.C.4.2. Inclusion of the signal in the periodic safety update report
(PSUR)
IX.C.4.3. Standalone signal notification
IX.C.5. Signal confirmation by the PRAC rapporteur or (lead) Member
State
IX.C.6. Signal analysis, prioritisation and assessment by the PRAC
IX.C.7. Recommendations on signals from the PRAC
IX.C.8. Record management in the European Pharmacovigilance Issues
Tracking Tool (EPITT)